Jazz Pharmaceuticals reported fourth quarter adjusted EPS of $1.72 after the bell Tuesday, which fell short of the consensus estimate of $1.78. Looking ahead to the fiscal 2014, the company has forecast adjusted EPS of $8.00 to $8.25. Analysts currently expect the company to report EPS of $8.07.<br /><br />The company also announced that Kathryn Falberg has resigned as the company's Executive Vice President and Chief Financial Officer, effective March 9. Matthew Young, senior vice president, has been elected to succeed Falberg.<br /><br />Jazz Pharmaceuticals gapped open sharply lower Wednesday and is now down 13.30 at $160.68. The stock has pulled back from the highs of the year and has set a week and a half low.